Haleon PLC ( (GB:HLN) ) just unveiled an announcement.
Haleon PLC has announced an agreement with Pfizer Inc. to purchase approximately £170 million worth of its own ordinary shares from Pfizer, contingent upon the completion of Pfizer’s proposed offering to institutional investors. This off-market purchase is part of Haleon’s £500 million share buyback plan for 2025, and the company intends to cancel the acquired shares, potentially impacting its market positioning and shareholder value.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers products across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements. Its portfolio includes well-known brands like Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
YTD Price Performance: 3.95%
Average Trading Volume: 24,429,550
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £35.04B
See more insights into HLN stock on TipRanks’ Stock Analysis page.